GW Pharmaceutical creating CBDV medications for treating Autism, Schizophrenia
A GW Pharmaceuticals cannabis patent application (2019/0160023) for the use of the cannabinoid cannabidivarin (CBDV) in the treatment of Autism, Schizophrenia, and related psychological disorders was published this month. Under GW Pharma’s Pharmaceutical Pipeline development, CBDV has entered into phase 2 of clinical trials. Once through phase 3, GW Pharma can submit an application to the FDA presenting their evidence to seek FDA approval of the purified CBDV drug, just as was done for their purified CBD drug Epidiolex.
Related Posts
Cannabis Popularity Soars Along With Tests To Detect It
The Duquenois Levine Test is used in the field by law enforcement officers to test for THC presence in a suspected sample. The problem with…
Hound Labs, Cannabix and Vox Heat Up the Marijuana Breathalyzer Market
At the start of April 2021, Patent Forecast® released an insight going over some of the big name competitors getting their foot in the door…
Driving While High? Cannabis Sobriety Testing Heats Up
What’s the future of cannabis innovation? We see things before they happen using our Patent Forecast®. One of those is the development of…